Development of a liposome microbicide formulation for vaginal delivery of octylglycerol for HIV prevention

References

• UNAIDS. UNAIDS Report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf.Accessed on 18 October 2011.
   Google Scholar
• Duerr A, Wasserheit JN, Corey L. (2006). HIV vaccines: New frontiers in vaccine development. Clin Infect Dis, 43:500–511.
   PubMed Web of Science ®Google Scholar
• Turpin JA. (2002). Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs, 11:1077–1097.
   PubMed Web of Science ®Google Scholar
• Moench TR, Chipato T, Padian NS. (2001). Preventing disease by protecting the cervix: The unexplored promise of internal vaginal barrier devices. AIDS, 15:1595–1602.
   PubMed Web of Science ®Google Scholar
• Sheryl L, Lard KLH David Feigal. (1994). Considerations in the Development of Vaginal Products Intended to Prevent the Sexual Transmission of HIV.
   Google Scholar
• Elias CJ, Coggins C. (1996). Female-controlled methods to prevent sexual transmission of HIV. AIDS, 10 Suppl 3:S43–S51.
   PubMed Web of Science ®Google Scholar
• Darroch JE, Frost JJ. (1999). Women’s interest in vaginal microbicides. Fam Plann Perspect, 31:16–23.
   PubMedGoogle Scholar
• McGowan I. (2006). Microbicides: A new frontier in HIV prevention. Biologicals, 34:241–255.
   PubMed Web of Science ®Google Scholar
• Maguire R. (2008). Microbicide product development. Curr Opin HIV AIDS, 3:554–557.
   PubMedGoogle Scholar
• Rohan LC, Sassi AB. (2009). Vaginal drug delivery systems for HIV prevention. AAPS J, 11:78–87.
   PubMed Web of Science ®Google Scholar
• Harrison PF, Rosenberg Z, Bowcut J. (2003). Topical microbicides for disease prevention: Status and challenges. Clin Infect Dis, 36:1290–1294.
   PubMed Web of Science ®Google Scholar
• Isaacs CE. (2001). The antimicrobial function of milk lipids. Adv Nutr Res, 10:271–285.
   PubMed Web of Science ®Google Scholar
• Isaacs CE, Thormar H. (1991). The role of milk-derived antimicrobial lipids as antiviral and antibacterial agents. Adv Exp Med Biol, 310:159–165.
   PubMedGoogle Scholar
• Li Q, Estes JD, Schlievert PM, Duan L, Brosnahan AJ, Southern PJ et al. (2009). Glycerol monolaurate prevents mucosal SIV transmission. Nature, 458:1034–1038.
   PubMed Web of Science ®Google Scholar
• Strandberg KL, Peterson ML, Lin YC, Pack MC, Chase DJ, Schlievert PM. (2010). Glycerol monolaurate inhibits Candida and Gardnerella vaginalis in vitro and in vivo but not Lactobacillus. Antimicrob Agents Chemother, 54:597–601.
   PubMed Web of Science ®Google Scholar
• Skinner MC, Kiselev AO, Isaacs CE, Mietzner TA, Montelaro RC, Lampe MF. (2010). Evaluation of WLBU2 peptide and 3-O-octyl-sn-glycerol lipid as active ingredients for a topical microbicide formulation targeting Chlamydia trachomatis. Antimicrob Agents Chemother, 54:627–636.
   PubMed Web of Science ®Google Scholar
• Moncla BJ, Pryke K, Isaacs CE. (2008). Killing of Neisseria gonorrhoeae,Streptococcus agalactiae (group B streptococcus), Haemophilus ducreyi, and vaginal Lactobacillus by 3-O-octyl-sn-glycerol. Antimicrob Agents Chemother, 52:1577–1579.
   PubMed Web of Science ®Google Scholar
• Chamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP. (2007). Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clin Ther, 29:1980–1986.
   PubMed Web of Science ®Google Scholar
• Vyas SP, Quraishi S, Gupta S, Jaganathan KS. (2005). Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm, 296:12–25.
   PubMed Web of Science ®Google Scholar
• Patel NA, Patel NJ, Patel RP. (2009). Design and evaluation of transdermal drug delivery system for curcumin as an anti-inflammatory drug. Drug Dev Ind Pharm, 35:234–242.
   PubMed Web of Science ®Google Scholar
• Hong RL, Tseng YL. (2001). Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: The relation between pharmacokinetic property and toxicity. Cancer, 91:1826–1833.
   PubMed Web of Science ®Google Scholar
• Panwar P, Pandey B, Lakhera PC, Singh KP. (2010). Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomedicine, 5:101–108.
   PubMed Web of Science ®Google Scholar
• Han HD, Lee A, Hwang T, Song CK, Seong H, Hyun J et al. (2007). Enhanced circulation time and antitumor activity of doxorubicin by comblike polymer-incorporated liposomes. J Control Release, 120:161–168.
   PubMed Web of Science ®Google Scholar
• Pollock S, Nichita NB, Böhmer A, Radulescu C, Dwek RA, Zitzmann N. (2010). Polyunsaturated liposomes are antiviral against hepatitis B and C viruses and HIV by decreasing cholesterol levels in infected cells. Proc Natl Acad Sci USA, 107:17176–17181.
   PubMed Web of Science ®Google Scholar
• Malavia NK, Zurakowski D, Schroeder A, Princiotto AM, Laury AR, Barash HE et al. (2011). Liposomes for HIV prophylaxis. Biomaterials, 32:8663–8668.
   PubMed Web of Science ®Google Scholar
• Zidan AS, Spinks C, Fortunak J, Habib M, Khan MA. (2010). Near-infrared investigations of novel anti-HIV tenofovir liposomes. AAPS J, 12:202–214.
   PubMed Web of Science ®Google Scholar
• Baker MT, Heriot W. (1999). Method and Apparatus for Liposome Production. USA patent US99/26738.
   Google Scholar
• Patton DL, Cosgrove-Sweeney YT, Rabe LK, Hillier SL. (2001). The pig-tailed macaque rectal model: Microflora and chlamydial infection. Sex Transm Dis, 28:363–366.
   PubMed Web of Science ®Google Scholar
• Patton DL, Sweeney YT, Paul KJ. (2009). A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis, 36:350–356.
   PubMed Web of Science ®Google Scholar
• Isaacs CE, Thormar H, Pessolano T. (1986). Membrane-disruptive effect of human milk: Inactivation of enveloped viruses. J Infect Dis, 154:966–971.
   PubMed Web of Science ®Google Scholar
• Reed LJ, Muench M. (1938). A simple method of estimating 50 percent end points. Am J Hyg, 27:493–497.
   Google Scholar
• Rohan LC, Ratner D, McCullough K, Hiller SL, Gupta P. (2004). Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay. Sex Transm Dis, 31:143–148.
   PubMed Web of Science ®Google Scholar
• Moncla BJ, Hillier SL. (2005). Why nonoxynol-9 may have failed to prevent acquisition of Neisseria gonorrhoeae in clinical trials. Sex Transm Dis, 32:491–494.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). US Department of Health and Human Services. Guidance for industry:Nonsterile semisolid dosage forms. Scale-Up and postapproval changes: Chemistry manufacturing, and controls; In vitro release testing and in vivo bioequivalence documentation. 1997 Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070930.pdf. Accessed on 21 January 2011.
   Google Scholar
• Wang L, Schnaare RL, Dezzutti C, Anton PA, Rohan LC. (2011). Rectal microbicides: Clinically relevant approach to the design of rectal specific placebo formulations. AIDS Res Ther, 8:12.
   PubMedGoogle Scholar
• Halpern V, Ogunsola F, Obunge O, Wang CH, Onyejepu N, Oduyebo O et al. (2008). Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: Results of a Phase III trial in Nigeria. PLoS ONE, 3:e3784.
   PubMed Web of Science ®Google Scholar
• Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML et al.; CS Study Group. (2008). Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med, 359:463–472.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T et al.; HIV Prevention Trials Network (HPTN) 035 Study Team. (2011). Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS, 25:957–966.
   PubMed Web of Science ®Google Scholar
• McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M et al. (2010). PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, double-blind, parallel-group trial. Lancet, 376:1329–1337.
   PubMed Web of Science ®Google Scholar
• Center for the AIDS Programme of research in South Africa (CAPRISA). Study of microbicide gel shows reduced risk of HIV & Herpes infection in women. XVIII International AIDS conference; Viennna, Austria 2010.
   Google Scholar
• Caron M, Besson G, Etenna SL, Mintsa-Ndong A, Mourtas S, Radaelli A et al. (2010). Protective properties of non-nucleoside reverse transcriptase inhibitor (MC1220) incorporated into liposome against intravaginal challenge of Rhesus macaques with RT-SHIV. Virology, 405:225–233.
   PubMed Web of Science ®Google Scholar
• Isaacs CE, Jia JH, Xu W. (2004). A lipid-peptide microbicide inactivates herpes simplex virus. Antimicrob Agents Chemother, 48:3182–3184.
   PubMed Web of Science ®Google Scholar
• Pavelic Z, Skalko-Basnet N, Jalsenjak I. (2005). Characterisation and in vitro evaluation of bioadhesive liposome gels for local therapy of vaginitis. Int J Pharm, 301:140–148.
   PubMed Web of Science ®Google Scholar
• Karn PR, Vanic Z, Pepic I, Skalko-Basnet N. (2011). Mucoadhesive liposomal delivery systems: The choice of coating material. Drug Dev Ind Pharm, 37:482–488.
   PubMed Web of Science ®Google Scholar
• Chen J, Ping QN, Guo JX, Chu XZ, Song MM. (2006). Effect of phospholipid composition on characterization of liposomes containing 9-nitrocamptothecin. Drug Dev Ind Pharm, 32:719–726.
   PubMed Web of Science ®Google Scholar
• Mehanna MM, Elmaradny HA, Samaha MW. (2009). Mucoadhesive liposomes as ocular delivery system: Physical, microbiological, and in vivo assessment. Drug Dev Ind Pharm, 36:108–118.
   Web of Science ®Google Scholar
• Qin J, Chen D, Lu W, Xu H, Yan C, Hu H et al. (2008). Preparation, characterization, and evaluation of liposomal ferulic acid in vitro and in vivo. Drug Dev Ind Pharm, 34:602–608.
   PubMed Web of Science ®Google Scholar
• Garg T, Jain S, Singh HP, Sharma A, Tiwary AK. (2008). Elastic liposomal formulation for sustained delivery of antimigraine drug: In vitro characterization and biological evaluation. Drug Dev Ind Pharm, 34:1100–1110.
   PubMed Web of Science ®Google Scholar
• Lu XY, Hu S, Jin Y, Qiu LY. (2011). Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug Dev Ind Pharm. DOI: 10.3109/03639045.2011.602410.
   Web of Science ®Google Scholar
• Ramana LN, Sethuraman S, Ranga U, Krishnan UM. (2010). Development of a liposomal nanodelivery system for nevirapine. J Biomed Sci, 17:57.
   PubMed Web of Science ®Google Scholar